{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T16:39:51Z","timestamp":1790959191644,"version":"4.1.0"},"reference-count":26,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2020,5,1]],"date-time":"2020-05-01T00:00:00Z","timestamp":1588291200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,5,1]],"date-time":"2020-05-01T00:00:00Z","timestamp":1588291200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,3,19]],"date-time":"2021-03-19T00:00:00Z","timestamp":1616112000000},"content-version":"am","delay-in-days":322,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","lungcancerjournal.info","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Lung Cancer"],"published-print":{"date-parts":[[2020,5]]},"DOI":"10.1016\/j.lungcan.2020.03.003","type":"journal-article","created":{"date-parts":[[2020,3,9]],"date-time":"2020-03-09T00:14:44Z","timestamp":1583712884000},"page":"19-26","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":110,"special_numbering":"C","title":["Cachexia - sarcopenia as a determinant of disease control rate and survival in non-small lung cancer patients receiving immune-checkpoint inhibitors"],"prefix":"10.1016","volume":"143","author":[{"given":"Beno\u00eet","family":"Roch","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amandine","family":"Coffy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandy","family":"Jean-Baptiste","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Estelle","family":"Palaysi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-Pierre","family":"Daures","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-Louis","family":"Pujol","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S\u00e9bastien","family":"Bommart","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.lungcan.2020.03.003_bib0005","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1038\/s12276-018-0191-1","article-title":"Immune checkpoint inhibitors: recent progress and potential biomarkers","volume":"50","author":"Darvin","year":"2018","journal-title":"Exp. Mol. Med."},{"key":"10.1016\/j.lungcan.2020.03.003_bib0010","doi-asserted-by":"crossref","first-page":"1627","DOI":"10.1056\/NEJMoa1507643","article-title":"Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer","volume":"373","author":"Borghaei","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.lungcan.2020.03.003_bib0015","doi-asserted-by":"crossref","first-page":"1823","DOI":"10.1056\/NEJMoa1606774","article-title":"Pembrolizumab versus chemotherapy for PD-L1-positive non-small-cell lung cancer","volume":"375","author":"Reck","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.lungcan.2020.03.003_bib0020","doi-asserted-by":"crossref","first-page":"2220","DOI":"10.1056\/NEJMoa1809064","article-title":"First-line atezolizumab plus chemotherapy in extensive-stage small-cell lung cancer","volume":"379","author":"Horn","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.lungcan.2020.03.003_bib0025","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1016\/j.jtho.2016.11.2228","article-title":"PD-L1 immunohistochemistry assays for lung cancer: results from phase 1 of the blueprint PD-L1 IHC assay comparison project","volume":"12","author":"Hirsch","year":"2017","journal-title":"J. Thorac. Oncol."},{"key":"10.1016\/j.lungcan.2020.03.003_bib0030","doi-asserted-by":"crossref","first-page":"2093","DOI":"10.1056\/NEJMoa1801946","article-title":"Nivolumab plus ipilimumab in lung cancer with a high tumor mutational burden","volume":"378","author":"Hellmann","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.lungcan.2020.03.003_bib0035","doi-asserted-by":"crossref","first-page":"1976","DOI":"10.1056\/NEJMoa1716078","article-title":"Neoadjuvant PD-1 blockade in resectable lung cancer","volume":"378","author":"Forde","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.lungcan.2020.03.003_bib0040","doi-asserted-by":"crossref","first-page":"822","DOI":"10.1158\/2159-8290.CD-18-0099","article-title":"STK11\/LKB1 mutations and PD-1 inhibitor resistance in KRAS-mutant lung adenocarcinoma","volume":"8","author":"Skoulidis","year":"2018","journal-title":"Cancer Discov."},{"key":"10.1016\/j.lungcan.2020.03.003_bib0045","doi-asserted-by":"crossref","first-page":"2447","DOI":"10.1038\/s41598-019-39120-6","article-title":"Impact of sarcopenia in patients with advanced non-small cell lung cancer treated with PD-1 inhibitors: a preliminary retrospective study","volume":"9","author":"Shiroyama","year":"2019","journal-title":"Sci. Rep."},{"key":"10.1016\/j.lungcan.2020.03.003_bib0050","doi-asserted-by":"crossref","first-page":"5841","DOI":"10.1158\/1078-0432.CCR-18-0415","article-title":"Pembrolizumab exposure-response assessments challenged by association of cancer cachexia and catabolic clearance","volume":"24","author":"Turner","year":"2018","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.lungcan.2020.03.003_bib0055","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1016\/j.molmed.2017.03.001","article-title":"Connecting the metabolic and immune responses to cancer","volume":"23","author":"Flint","year":"2017","journal-title":"Trends Mol. Med."},{"key":"10.1016\/j.lungcan.2020.03.003_bib0060","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1016\/S1470-2045(10)70218-7","article-title":"Definition and classification of cancer cachexia: an international consensus","volume":"12","author":"Fearon","year":"2011","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.lungcan.2020.03.003_bib0065","doi-asserted-by":"crossref","first-page":"1635","DOI":"10.1093\/annonc\/mdu086","article-title":"Validation of the Consensus-Definition for Cancer Cachexia and evaluation of a classification model--a study based on data from an international multicentre project (EPCRC-CSA)","volume":"25","author":"Blum","year":"2014","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.lungcan.2020.03.003_bib0070","doi-asserted-by":"crossref","first-page":"W221","DOI":"10.2214\/AJR.09.3928","article-title":"New Response Evaluation Criteria in Solid Tumors (RECIST) guidelines for advanced non-small cell lung cancer: comparison with original RECIST and impact on assessment of tumor response to targeted therapy","volume":"195","author":"Nishino","year":"2010","journal-title":"Am. J. Roentgenol."},{"key":"10.1016\/j.lungcan.2020.03.003_bib0075","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1016\/S1470-2045(08)70153-0","article-title":"Prevalence and clinical implications of sarcopenic obesity in patients with solid tumours of the respiratory and gastrointestinal tracts: a population-based study","volume":"9","author":"Prado","year":"2008","journal-title":"Lancet Oncol."},{"issue":"15_suppl","key":"10.1016\/j.lungcan.2020.03.003_bib0080","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2018.36.15_suppl.9010","article-title":"Efficacy of immune-checkpoint inhibitors (ICPI) in non-small cell lung cancer patients harboring activating molecular alterations (ImmunoTarget)","volume":"36","author":"Mazieres","year":"2018","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.lungcan.2020.03.003_bib0085","doi-asserted-by":"crossref","first-page":"873","DOI":"10.1016\/j.jtho.2016.02.013","article-title":"Early weight loss during chemoradiotherapy has a detrimental impact on outcome in NSCLC","volume":"11","author":"Sanders","year":"2016","journal-title":"J. Thorac. Oncol."},{"key":"10.1016\/j.lungcan.2020.03.003_bib0090","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1126\/science.aaa6204","article-title":"T cell exclusion, immune privilege, and the tumor microenvironment","volume":"348","author":"Joyce","year":"2015","journal-title":"Science"},{"key":"10.1016\/j.lungcan.2020.03.003_bib0095","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1038\/s12276-018-0130-1","article-title":"Future prospects of immune checkpoint blockade in cancer: from response prediction to overcomingresistance","volume":"50","author":"Park","year":"2018","journal-title":"Exp. Mol. Med."},{"key":"10.1016\/j.lungcan.2020.03.003_bib0100","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1093\/annonc\/mdy553","article-title":"Position of a panel of international lung cancer experts on the approval decision for use of durvalumab in stage III non-small-cell lung cancer (NSCLC) by the Committee for Medicinal Products for Human Use (CHMP)","volume":"30","author":"Peters","year":"2019","journal-title":"Ann. Oncol."},{"issue":"Suppl. 1","key":"10.1016\/j.lungcan.2020.03.003_bib0105","doi-asserted-by":"crossref","first-page":"S89","DOI":"10.21037\/jtd.2018.12.103","article-title":"Programmed death ligand 1immunohistochemistry in non-small cell lung carcinoma","volume":"11","author":"Lantuejoul","year":"2019","journal-title":"J. Thorac. Dis."},{"key":"10.1016\/j.lungcan.2020.03.003_bib0110","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1038\/s41588-018-0312-8","article-title":"Tumor mutational load predicts survival after immunotherapy across multiple cancer types","volume":"51","author":"Samstein","year":"2019","journal-title":"Nat. Genet."},{"key":"10.1016\/j.lungcan.2020.03.003_bib0115","doi-asserted-by":"crossref","first-page":"1852","DOI":"10.1038\/s41591-018-0255-8","article-title":"(89)Zr-atezolizumab imaging as a non-invasive approach to assess clinical response to PD-L1 blockade in cancer","volume":"24","author":"Bensch","year":"2018","journal-title":"Nat. Med."},{"key":"10.1016\/j.lungcan.2020.03.003_bib0120","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1016\/j.jtho.2016.04.010","article-title":"Is Weight Loss a Loss of Chance in Patients Receiving Chemoradiotherapy?","volume":"11","author":"Pujol","year":"2016","journal-title":"J. Thorac. Oncol."},{"key":"10.1016\/j.lungcan.2020.03.003_bib0125","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1016\/S1470-2045(15)00558-6","article-title":"Anamorelin in patients with non-small-cell lung cancer and cachexia (ROMANA 1 and ROMANA 2): results from two randomised, double-blind, phase 3 trials","volume":"17","author":"Temel","year":"2016","journal-title":"Lancet Oncol."},{"issue":"suppl_5","key":"10.1016\/j.lungcan.2020.03.003_bib0130","first-page":"v460","article-title":"IFCT-1502 CLINIVO: real-life experience with nivolumab in 600 patients (pts) with advanced Non-Small Cell Lung Cancer (NSCLC): efficacy and safety","volume":"28","author":"Girard","year":"2017","journal-title":"Ann. Oncol."}],"container-title":["Lung Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0169500220303196?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0169500220303196?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,30]],"date-time":"2025-09-30T12:35:11Z","timestamp":1759235711000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0169500220303196"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,5]]},"references-count":26,"alternative-id":["S0169500220303196"],"URL":"https:\/\/doi.org\/10.1016\/j.lungcan.2020.03.003","relation":{},"ISSN":["0169-5002"],"issn-type":[{"value":"0169-5002","type":"print"}],"subject":[],"published":{"date-parts":[[2020,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Cachexia - sarcopenia as a determinant of disease control rate and survival in non-small lung cancer patients receiving immune-checkpoint inhibitors","name":"articletitle","label":"Article Title"},{"value":"Lung Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.lungcan.2020.03.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}